• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Response to ''To switch or not to switch': the missing piece in the puzzle of biosimilar literature?' by Scherlinger .

作者信息

Glintborg Bente, Loft Anne Gitte, Omerovic Emina, Hendricks Oliver, Linauskas Asta, Espesen Jakob, Danebod Kamilla, Jensen Dorte Vendelbo, Nordin Henrik, Dalgaard Emil Barner, Chrysidis Stavros, Kristensen Salome, Raun Johnny Lillelund, Lindegaard Hanne, Manilo Natalia, Jakobsen Susanne Højmark, Hansen Inger Marie Jensen, Pedersen Dorte Dalsgaard, Sørensen Inge Juul, Andersen Lis Smedegaard, Grydehøj Jolanta, Mehnert Frank, Krogh Niels Steen, Lund Hetland Merete

机构信息

The DANBIO Registry and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Glostrup, Denmark

Department of Rheumatology, Gentofte and Herlev Hospital, Copenhagen University Hospital, Gentofte, Denmark.

出版信息

Ann Rheum Dis. 2020 Apr;79(4):e37. doi: 10.1136/annrheumdis-2018-214952. Epub 2019 Jan 23.

DOI:10.1136/annrheumdis-2018-214952
PMID:30674476
Abstract
摘要

相似文献

1
Response to ''To switch or not to switch': the missing piece in the puzzle of biosimilar literature?' by Scherlinger .对舍林格所著《“转换还是不转换”：生物类似药文献谜题中缺失的一环？》的回应
Ann Rheum Dis. 2020 Apr;79(4):e37. doi: 10.1136/annrheumdis-2018-214952. Epub 2019 Jan 23.
2
'To switch or not to switch': the missing piece in the puzzle of biosimilar literature?“换还是不换”：生物类似药文献拼图中缺失的一块？
Ann Rheum Dis. 2020 Apr;79(4):e36. doi: 10.1136/annrheumdis-2018-214908. Epub 2019 Jan 4.
3
Response to: 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB: possible fallout on non-medical switching' by Cantini and Benucci.对坎蒂尼和贝努奇所著《强制、成本驱动下从原研依那西普转换为其生物类似药SB：非医学转换可能产生的影响》的回应
Ann Rheum Dis. 2020 Feb;79(2):e14. doi: 10.1136/annrheumdis-2018-214788. Epub 2018 Dec 20.
4
Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching.强制的、成本驱动的从原研药依那西普转换为其生物类似药SB4：对非医学转换可能产生的影响。
Ann Rheum Dis. 2020 Feb;79(2):e13. doi: 10.1136/annrheumdis-2018-214757. Epub 2018 Nov 28.
5
To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry.是否切换：全国强制性从原研药切换至生物类似药依那西普的指南结果。DANBIO 登记处 2061 例炎性关节炎患者的 1 年治疗结果。
Ann Rheum Dis. 2019 Feb;78(2):192-200. doi: 10.1136/annrheumdis-2018-213474. Epub 2018 Nov 5.
6
Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4).从原研药到生物类似药依那西普（SB4）转换过程中的接受率和社会学因素。
Semin Arthritis Rheum. 2019 Apr;48(5):927-932. doi: 10.1016/j.semarthrit.2018.07.005. Epub 2018 Jul 20.
7
Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA.依那西普原研药与依那西普生物类似药治疗类风湿关节炎作为一线生物制剂的比较：来自 BSRBR-RA 的结果。
Rheumatology (Oxford). 2023 Dec 1;62(12):3849-3857. doi: 10.1093/rheumatology/kead127.
8
Comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another consideration.比较依那西普生物类似药SB4与原研依那西普的免疫原性：另一项考量
Ann Rheum Dis. 2016 Jul;75(7):e37. doi: 10.1136/annrheumdis-2016-209502. Epub 2016 Mar 31.
9
Post-switch Effectiveness of Etanercept Biosimilar Versus Continued Etanercept in Rheumatoid Arthritis Patients with Stable Disease: A Prospective Multinational Observational Study.依那西普生物类似药转换治疗与继续使用依那西普治疗对病情稳定的类风湿关节炎患者的疗效：一项前瞻性多国观察性研究。
Adv Ther. 2022 Nov;39(11):5259-5273. doi: 10.1007/s12325-022-02303-1. Epub 2022 Sep 22.
10
Response to: 'Comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another consideration' by Marshall et al.对马歇尔等人所著《比较依那西普生物类似药SB4与原研依那西普的免疫原性：另一个考量因素》的回应
Ann Rheum Dis. 2016 Jul;75(7):e38. doi: 10.1136/annrheumdis-2016-209517. Epub 2016 May 4.

引用本文的文献

1
Era of biosimilars in rheumatology: reshaping the healthcare environment.生物类似药时代：重塑医疗保健环境。
RMD Open. 2019 May 21;5(1):e000900. doi: 10.1136/rmdopen-2019-000900. eCollection 2019.